Delaying Treatment Worsens Head, Neck Cancer Outcomes
Findings show that survival declines, recurrence increases with delays of more than 60 days.
Head and Neck Cancer News
HEAD AND NECK CANCER ADVISOR
Head and Neck Cancer News
Adjuvant Radiation Therapy Improved Outcomes for Some With Advanced Head and Neck CSCC
Researchers determined the 5-year overall and disease-free survival for patients with CSCC of the head and neck who received adjuvant radiation therapy.
Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Which Feeding Tubes Do Head and Neck Cancer Clinicians Prefer to Use in Patients Undergoing Radiotherapy?
Nasogastric tubes placed reactively or gastrostomy tubes placed prophylactically? Head and neck cancer experts weigh in on which they, and their patients, prefer to use.
Practice Setting Linked to Receipt of More Costly Cancer Drugs
Receiving cancer treatment at a non–National Cancer Institute-designated Comprehensive Cancer Center was associated with higher drug cost, a cohort study found.
Rates of Head, Neck Melanoma Up in North American Youth
Risk for head, neck melanoma higher for male sex, older age, non-Hispanic white ethnicity
Incidence of HPV-Positive Head and Neck Cancer Up in the U.S.
From 2013 to 2014, incidence of HPV-positive oropharyngeal cancers was 4.62 per 100,000 persons.
ASTRO: NSAIDs May Offer Benefit to Head & Neck Cancer Patients
Benefit not significant for aspirin use in patients with non-small cell lung cancer undergoing SBRT.
Immunological Profiling of High-Grade Gliomas Reveals Subtypes That Influence Survival
Four distinct immunologic groups independent of patient age were identified and correlated with overall survival in patients with high-grade glioma.
Baseline Dysphagia May Predict Response to Treatment, Survival in Esophageal Cancer
Patients with higher dysphagia scores also experienced worse febrile neutropenia and diarrhea.
Following NCCN Surveillance Guidelines in Oropharyngeal Carcinoma Did Not Yield a Survival Benefit: Study
Patients with HPV–associated oropharyngeal squamous cell carcinoma who adhered to the NCCN clinical surveillance recommendations did have improved survival.
Minority, Low-Income Individuals Less Likely to Receive Oral Cancer Screening
Education level, insurance type also may affect likelihood of oral cancer screening at dental visit.
Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
Incidence of HPV-Positive OPSCC Is Double That Seen in HPV-Negative Disease
Incidence was greatest among white men aged 60 to 64 years.
Post-Op Radiation Safely Eliminated in Node-Negative Neck HNSCC
Elimination of radiation therapy did not alter quality-of-life outcomes.
Age Does Not Impact Survival After Transthoracic Esophagectomy, Study Finds
Age was not a significant prognostic factor for long-term survival after transthoracic esophagectomy among patients with thoracic esophageal cancer.
Statins May Be Beneficial After Radiation to Thorax, Head, Neck
Statin use tied to reduction in stroke incidence for cardiac patients with thorax and head or neck cancer.
Keytruda Approved for First Line Treatment of Unresectable, Recurrent HNSCC
The FDA has approved Keytruda (pembrolizumab; Merck) for first line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression.
Mouth Rinse for HPV DNA May Be Biomarker in Head, Neck Cancer
Human papillomavirus (HPV) DNA detected from a mouth rinse may be an effective marker for prognosis during treatment of HPV-positive head and neck cancer
Want to read more?
Please login or register first to view this content.
